BRAINSTORM CELL THERAPEUTICS's ticker is and the CUSIP is 10501E951. A total of 3 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20 | -79.6% | 100,700 | +109.8% | 0.00% | – |
| Q2 2023 | $98 | +92.2% | 48,000 | +205.7% | 0.00% | – |
| Q1 2023 | $51 | +240.0% | 15,700 | +67.0% | 0.00% | – |
| Q4 2022 | $15 | -100.0% | 9,400 | -34.7% | 0.00% | – |
| Q3 2022 | $63,000 | +687.5% | 14,400 | +364.5% | 0.00% | – |
| Q2 2022 | $8,000 | -66.7% | 3,100 | -57.5% | 0.00% | – |
| Q1 2022 | $24,000 | -90.5% | 7,300 | -88.5% | 0.00% | – |
| Q4 2021 | $253,000 | -25.4% | 63,400 | -29.2% | 0.00% | – |
| Q3 2021 | $339,000 | -0.3% | 89,600 | 0.0% | 0.00% | – |
| Q2 2021 | $340,000 | -20.6% | 89,600 | +7914.3% | 0.00% | -100.0% |
| Q1 2021 | $428,000 | +100.9% | 1,118 | +136.9% | 0.00% | – |
| Q4 2020 | $213,000 | -38.4% | 472 | +130.2% | 0.00% | – |
| Q3 2020 | $346,000 | +98.9% | 205 | +31.4% | 0.00% | – |
| Q2 2020 | $174,000 | -20.9% | 156 | -67.2% | 0.00% | – |
| Q1 2020 | $220,000 | +266.7% | 476 | +209.1% | 0.00% | – |
| Q3 2019 | $60,000 | -23.1% | 154 | -22.6% | 0.00% | – |
| Q2 2019 | $78,000 | -12.4% | 199 | -3.4% | 0.00% | – |
| Q1 2019 | $89,000 | +8800.0% | 206 | +1960.0% | 0.00% | – |
| Q4 2017 | $1,000 | 0.0% | 10 | 0.0% | 0.00% | – |
| Q3 2017 | $1,000 | – | 10 | +400.0% | 0.00% | – |
| Q2 2017 | $0 | -100.0% | 2 | -80.0% | 0.00% | – |
| Q1 2017 | $1,000 | -50.0% | 10 | -83.3% | 0.00% | – |
| Q4 2016 | $2,000 | – | 60 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GROUP ONE TRADING, L.P. | 18,200 | $80,000 | 0.00% |
| SIMPLEX TRADING, LLC | 14,400 | $63,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |